Philip Felgner

Last updated
Philip Felgner
Born
Philip Louis Felgner

(1950-02-07) 7 February 1950 (age 74)
Frankenmuth, Michigan, United States
Alma mater Michigan State University
Scientific career
Fields

Philip Louis Felgner (born 7 February 1950) is an American biochemists and immunologists, specialized in lipofection technology and genetics. He is one of the developers of the vaccine against the SARS-CoV-2 virus, responsible for COVID-19 pandemic.

In 1972, he graduated in biochemistry from the Michigan State University, earning his master's degree in 1975 and his Ph.D. in 1978. He did postdoctoral work at the University of Virginia. [1]

In 2021, he was awarded the Princess of Asturias Awards for Technical and Scientific Research along Katalin Karikó, Drew Weissman, Uğur Şahin, Özlem Türeci, Derrick Rossi, and Sarah Gilbert. [2]

Related Research Articles

<span class="mw-page-title-main">Princess of Asturias Awards</span> Annual prizes awarded in Spain

The Princess of Asturias Awards, formerly the Prince of Asturias Awards from 1981 to 2014, are a series of annual prizes awarded in Spain by the Princess of Asturias Foundation to individuals, entities or organizations from around the world who make notable achievements in the sciences, humanities, and public affairs.

Lasker–DeBakey Clinical Medical Research Award is one of four annual awards presented by the Lasker Foundation. The Lasker–DeBakey award is given to honor outstanding work for the understanding, diagnosis, prevention, treatment, and cure of disease. This award was renamed in 2008 in honor of Michael E. DeBakey. It was previously known as the Albert Lasker Award for Clinical Medical Research.

The Louisa Gross Horwitz Prize for Biology or Biochemistry is an annual prize awarded by Columbia University to a researcher or group of researchers who have made an outstanding contribution in basic research in the fields of biology or biochemistry.

The William B. Coley Award for Distinguished Research in Basic and Tumor Immunology is presented annually by the Cancer Research Institute, to scientists who have made outstanding achievements in the fields of basic and tumor immunology and whose work has deepened our understanding of the immune system's response to disease, including cancer.

<span class="mw-page-title-main">Louis-Jeantet Prize for Medicine</span> Swiss medicine award

Established in 1986, the Louis-Jeantet Prizes are funded by the Fondation Louis-Jeantet and awarded each year to experienced researchers who have distinguished themselves in the field of biomedical research in one of the member states of the Council of Europe. They are not intended solely as the recognition of work that has been completed, but also to encourage the continuation of innovative research projects. The prizes are awarded to fully active researchers whose scientific efforts are focused on biomedical research. When the research being recognised is close to practical applications for combating illnesses affecting humankind, one of the Louis-Jeantet Prizes converts into a Jeantet-Collen Prize for Translational Medicine, supported by generous donations from the Désiré Collen Stichting.

The Albany Medical Center Prize in Medicine and Biomedical Research is the United States' second highest value prize in medicine and biomedical research, awarded by the Albany Medical Center. Among prizes for medicine worldwide, the Albany Medical Center Prize is the fourth most lucrative.

The Paul Ehrlich and Ludwig Darmstaedter Prize is an annual award bestowed by the Paul Ehrlich Foundation since 1952 for investigations in medicine. It carries a prize money of 120,000 Euro. The prize awarding ceremony is traditionally held on 14 March, the birthday of Nobel laureate Paul Ehrlich, in the St. Paul's Church, Frankfurt am Main.

The Meyenburg Prize is awarded for outstanding achievements in cancer research by the Meyenburg Foundation in support of the German Cancer Research Center, Heidelberg (DKFZ), which is the largest biomedical research institution in Germany. The prize has been awarded annually since 1981, and currently has an honorarium of €50,000.

<span class="mw-page-title-main">Derrick Rossi</span> Canadian stem cell biologist

Derrick J. Rossi, is a Canadian stem cell biologist and entrepreneur. He is a co-founder of the pharmaceutical company Moderna.

<span class="mw-page-title-main">Sarah Gilbert</span> English vaccinologist (born 1962)

Dame Sarah Catherine Gilbert FRS is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.

<span class="mw-page-title-main">Katalin Karikó</span> Hungarian-American biochemist (born 1955)

Katalin "Kati" Karikó is a Hungarian-American biochemist who specializes in ribonucleic acid (RNA)-mediated mechanisms, particularly in vitro-transcribed messenger RNA (mRNA) for protein replacement therapy. Karikó laid the scientific groundwork for mRNA vaccines, overcoming major obstacles and skepticism in the scientific community. Karikó received the Nobel Prize in Physiology or Medicine in 2023 for her work, along with American immunologist Drew Weissman.

<span class="mw-page-title-main">Uğur Şahin</span> German oncologist and immunologist (born 1965)

Uğur Şahin is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.

<span class="mw-page-title-main">Özlem Türeci</span> German physician, scientist and entrepreneur

Özlem Türeci is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology (HI-TRON) and Johannes Gutenberg University Mainz. Türeci and her spouse, Uğur Şahin, have won a number of awards.

<span class="mw-page-title-main">ALC-0315</span> Chemical compound

ALC-0315 is a synthetic lipid. A colorless oily material, it has attracted attention as a component of the SARS-CoV-2 vaccine, BNT162b2, from BioNTech and Pfizer. Specifically, it is one of four components that form lipid nanoparticles (LNPs), which encapsulate and protect the otherwise fragile mRNA that is the active ingredient in these drugs. These nanoparticles promote the uptake of therapeutically effective nucleic acids such as oligonucleotides or mRNA both in vitro and in vivo.

<span class="mw-page-title-main">Drew Weissman</span> American physician and immunologist (born 1959)

Drew Weissman is an American physician and immunologist known for his contributions to RNA biology. Weissman is the inaugural Roberts Family Professor in Vaccine Research, director of the Penn Institute for RNA Innovation, and professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).

Robert Wallace Malone is an American physician and biochemist. His early work focused on mRNA technology, pharmaceuticals, and drug repurposing research. During the COVID-19 pandemic, Malone promoted misinformation about the safety and efficacy of COVID-19 vaccines.

<span class="mw-page-title-main">2023 Nobel Prize in Physiology or Medicine</span> Award

The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".

References

  1. Philip L. Felgner UCI profile
  2. "Katalin Karikó, Drew Weissman, Philip Felgner, Uğur Şahin, Özlem Türeci, Derrick Rossi, and Sarah Gilbert, Princess of Asturias Award for Technical and Scientific Research 2021". Princess of Asturias Foundation. 23 June 2021.